Gilead Sciences INC (GILD) Share Price Declined While Sentinel Trust Company Lba Has Lowered Its Position

August 9, 2018 - By Palma Niemeyer

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It increased, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Charter Trust Co accumulated 16,014 shares or 0.15% of the stock. Gradient Limited Liability Company holds 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 545 shares. Marshall Wace Llp invested 0.63% in Gilead Sciences, Inc. (NASDAQ:GILD). First Bancorp accumulated 16,468 shares. Stonebridge Ltd Co accumulated 79,042 shares or 1.37% of the stock. First Quadrant LP Ca reported 47,197 shares. Boston Common Asset Lc holds 0.66% or 74,163 shares. Plancorp Lc owns 16,872 shares. Etrade Capital Ltd Company, a New York-based fund reported 32,086 shares. Hartford Investment Mgmt holds 0.4% or 263,981 shares. 28,726 are owned by Systematic Financial Mngmt Lp. Duncker Streett & Comm Incorporated has invested 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD). Becker Management owns 732,040 shares. Ferguson Wellman Cap Inc has 0.09% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 35,455 shares. City Hldgs holds 23,490 shares.

Since February 9, 2018, it had 0 insider purchases, and 17 sales for $25.62 million activity. $1.97 million worth of stock was sold by Alton Gregg H on Thursday, March 1. 5,833 shares valued at $430,130 were sold by Cogan John Francis on Friday, April 20. Washington Robin L sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 21. $4.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by WILSON GAYLE E on Friday, February 9.

Sentinel Trust Company Lba decreased its stake in Gilead Sciences Inc (GILD) by 67.2% based on its latest 2018Q1 regulatory filing with the SEC. Sentinel Trust Company Lba sold 42,315 shares as the company’s stock declined 17.62% with the market. The institutional investor held 20,655 shares of the health care company at the end of 2018Q1, valued at $1.56M, down from 62,970 at the end of the previous reported quarter. Sentinel Trust Company Lba who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $101.52B market cap company. The stock increased 1.82% or $1.4 during the last trading session, reaching $78.31. About 2.37 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since August 9, 2017 and is uptrending. It has underperformed by 8.20% the S&P500.

Sentinel Trust Company Lba, which manages about $473.46M US Long portfolio, upped its stake in Alexion Pharmaceutical Com (NASDAQ:ALXN) by 36,965 shares to 70,920 shares, valued at $7.91M in 2018Q1, according to the filing.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on October, 25. They expect $1.54 EPS, down 30.94 % or $0.69 from last year’s $2.23 per share. GILD’s profit will be $2.00B for 12.71 P/E if the $1.54 EPS becomes a reality. After $1.75 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -12.00 % negative EPS growth.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead: A Bell Tolls, And A Window Of Opportunity Opens” on August 06, 2018, also Seekingalpha.com with their article: “Gilead: Cheap Valuation For Great Pipeline” published on July 12, 2018, Nasdaq.com published: “Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates” on July 25, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: Is The Drama Over?” published on August 01, 2018 as well as Nasdaq.com‘s news article titled: “Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?” with publication date: July 23, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 9 analysts covering Gilead Sciences (NASDAQ:GILD), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Gilead Sciences had 12 analyst reports since February 12, 2018 according to SRatingsIntel. The company was maintained on Wednesday, May 2 by RBC Capital Markets. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Overweight” rating given on Tuesday, March 6 by Barclays Capital. The stock has “Buy” rating by Piper Jaffray on Wednesday, May 30. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, July 26. Barclays Capital maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, May 2. Barclays Capital has “Overweight” rating and $90 target. The firm has “Buy” rating by Mizuho given on Monday, February 12. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Wednesday, May 2 by Leerink Swann. Leerink Swann maintained the stock with “Hold” rating in Thursday, February 22 report. Robert W. Baird downgraded the stock to “Neutral” rating in Thursday, July 26 report. On Wednesday, May 2 the stock rating was maintained by Morgan Stanley with “Equal-Weight”.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.